Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell- Lymphoma- Presented at ASH 2018
Shots:
- The ZUMA-1 trial involves assessing of Yescarta in patients with refractory large B-cell lymphoma for a duration of two years
- ZUMA-1 trial results (N=101): OR 83%; CR 58%; median follow up @27.1- 24 mos. (39%- 93% remain in response); mDOR 11.1 mos.; with no new safety signals observed
- Yescarta (axicabtagene ciloleucel) is novel CAR T therapy approved by FDA for 2L+ r/r large B-cell lymphoma. The US PI involves a box warning with the usage of Yescarta leading to Cytokine Release Syndrome (CRS) & Neurologic toxicities
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
